The association of medication use with clearance or persistence of oral HPV infection

Jennifer O. Lam, Elizabeth A. Sugar, Ross D. Cranston, Kathleen M. Weber, Robert D. Burk, Dorothy J. Wiley, Susheel Reddy, Joseph B. Margolick, Howard Strickler, Alicia Wentz, Lisa Jacobson, Christian L. Coles, Jay H. Bream, Anne F. Rositch, Yingshi Guo, Weihong Xiao, Maura L. Gillison, Gypsyamber D’Souza

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Persistent oral human papillomavirus (HPV) infection increases risk for oropharyngeal carcinoma, and people living with HIV have higher rates of oral HPV infection and related cancers. Some prescription medications have immunomodulatory effects, but the impact of medication use on oral HPV natural history is unknown. Methods: Scope® oral rinse-and-gargle samples were collected semi-annually from 1,666 participants and tested for 37 types of oral HPV DNA using PCR; 594 HPV-infected participants with 1,358 type-specific oral HPV infections were identified. Data were collected on recent (past 6 months) use of medications. The relationship between medication use and oral HPV clearance was evaluated using Wei–Lin–Weissfeld regression, adjusting for biologic sex, prevalent versus incident infection, age, HIV status and CD4+ T cell count. Results: Out of 11 medications examined, oral HPV clearance was significantly reduced in participants reporting recent use of antipsychotics (HR 0.75, 95% CI 0.57–0.99), anxiolytics/sedatives (HR 0.78, 95% CI 0.63–0.96) and antidepressants (HR 0.82, 95% CI 0.67–0.999). Among antipsychotics users, effect modification by HIV status was observed, with reduced clearance in HIV-infected (HR 0.67, 95% CI 0.49–0.91), but not HIV-uninfected participants (p-interaction = 0.009). After adjusted analysis, antipsychotic use remained significantly associated with reduced oral HPV clearance overall (aHR 0.75, 95% CI 0.57–0.99), and when restricted to only HIV-infected participants (aHR 0.66, 95% CI 0.48–0.90). After adjustment, anxiolytic/sedative use and antidepressant use were no longer significantly associated with reduced oral HPV clearance. Conclusions: Some medications were associated with decreased oral HPV clearance, most notably antipsychotic medications. These medications are prescribed for conditions that may have immunomodulating effects, so characteristics of underlying illness may have partially contributed to reduced oral HPV clearance.

Original languageEnglish (US)
Pages (from-to)1491-1498
Number of pages8
JournalCancer Causes and Control
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Papillomavirus Infections
Antipsychotic Agents
HIV
Anti-Anxiety Agents
Hypnotics and Sedatives
Antidepressive Agents
CD4 Lymphocyte Count
Natural History
HIV Infections
Prescriptions

Keywords

  • Antipsychotic
  • Clearance
  • HIV
  • Immunomodulatory
  • Oral HPV
  • Prescription medication

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lam, J. O., Sugar, E. A., Cranston, R. D., Weber, K. M., Burk, R. D., Wiley, D. J., ... D’Souza, G. (2016). The association of medication use with clearance or persistence of oral HPV infection. Cancer Causes and Control, 27(12), 1491-1498. https://doi.org/10.1007/s10552-016-0826-2

The association of medication use with clearance or persistence of oral HPV infection. / Lam, Jennifer O.; Sugar, Elizabeth A.; Cranston, Ross D.; Weber, Kathleen M.; Burk, Robert D.; Wiley, Dorothy J.; Reddy, Susheel; Margolick, Joseph B.; Strickler, Howard; Wentz, Alicia; Jacobson, Lisa; Coles, Christian L.; Bream, Jay H.; Rositch, Anne F.; Guo, Yingshi; Xiao, Weihong; Gillison, Maura L.; D’Souza, Gypsyamber.

In: Cancer Causes and Control, Vol. 27, No. 12, 01.12.2016, p. 1491-1498.

Research output: Contribution to journalArticle

Lam, JO, Sugar, EA, Cranston, RD, Weber, KM, Burk, RD, Wiley, DJ, Reddy, S, Margolick, JB, Strickler, H, Wentz, A, Jacobson, L, Coles, CL, Bream, JH, Rositch, AF, Guo, Y, Xiao, W, Gillison, ML & D’Souza, G 2016, 'The association of medication use with clearance or persistence of oral HPV infection', Cancer Causes and Control, vol. 27, no. 12, pp. 1491-1498. https://doi.org/10.1007/s10552-016-0826-2
Lam, Jennifer O. ; Sugar, Elizabeth A. ; Cranston, Ross D. ; Weber, Kathleen M. ; Burk, Robert D. ; Wiley, Dorothy J. ; Reddy, Susheel ; Margolick, Joseph B. ; Strickler, Howard ; Wentz, Alicia ; Jacobson, Lisa ; Coles, Christian L. ; Bream, Jay H. ; Rositch, Anne F. ; Guo, Yingshi ; Xiao, Weihong ; Gillison, Maura L. ; D’Souza, Gypsyamber. / The association of medication use with clearance or persistence of oral HPV infection. In: Cancer Causes and Control. 2016 ; Vol. 27, No. 12. pp. 1491-1498.
@article{f91d5d128c464085a23d90c123563675,
title = "The association of medication use with clearance or persistence of oral HPV infection",
abstract = "Purpose: Persistent oral human papillomavirus (HPV) infection increases risk for oropharyngeal carcinoma, and people living with HIV have higher rates of oral HPV infection and related cancers. Some prescription medications have immunomodulatory effects, but the impact of medication use on oral HPV natural history is unknown. Methods: Scope{\circledR} oral rinse-and-gargle samples were collected semi-annually from 1,666 participants and tested for 37 types of oral HPV DNA using PCR; 594 HPV-infected participants with 1,358 type-specific oral HPV infections were identified. Data were collected on recent (past 6 months) use of medications. The relationship between medication use and oral HPV clearance was evaluated using Wei–Lin–Weissfeld regression, adjusting for biologic sex, prevalent versus incident infection, age, HIV status and CD4+ T cell count. Results: Out of 11 medications examined, oral HPV clearance was significantly reduced in participants reporting recent use of antipsychotics (HR 0.75, 95{\%} CI 0.57–0.99), anxiolytics/sedatives (HR 0.78, 95{\%} CI 0.63–0.96) and antidepressants (HR 0.82, 95{\%} CI 0.67–0.999). Among antipsychotics users, effect modification by HIV status was observed, with reduced clearance in HIV-infected (HR 0.67, 95{\%} CI 0.49–0.91), but not HIV-uninfected participants (p-interaction = 0.009). After adjusted analysis, antipsychotic use remained significantly associated with reduced oral HPV clearance overall (aHR 0.75, 95{\%} CI 0.57–0.99), and when restricted to only HIV-infected participants (aHR 0.66, 95{\%} CI 0.48–0.90). After adjustment, anxiolytic/sedative use and antidepressant use were no longer significantly associated with reduced oral HPV clearance. Conclusions: Some medications were associated with decreased oral HPV clearance, most notably antipsychotic medications. These medications are prescribed for conditions that may have immunomodulating effects, so characteristics of underlying illness may have partially contributed to reduced oral HPV clearance.",
keywords = "Antipsychotic, Clearance, HIV, Immunomodulatory, Oral HPV, Prescription medication",
author = "Lam, {Jennifer O.} and Sugar, {Elizabeth A.} and Cranston, {Ross D.} and Weber, {Kathleen M.} and Burk, {Robert D.} and Wiley, {Dorothy J.} and Susheel Reddy and Margolick, {Joseph B.} and Howard Strickler and Alicia Wentz and Lisa Jacobson and Coles, {Christian L.} and Bream, {Jay H.} and Rositch, {Anne F.} and Yingshi Guo and Weihong Xiao and Gillison, {Maura L.} and Gypsyamber D’Souza",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10552-016-0826-2",
language = "English (US)",
volume = "27",
pages = "1491--1498",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "12",

}

TY - JOUR

T1 - The association of medication use with clearance or persistence of oral HPV infection

AU - Lam, Jennifer O.

AU - Sugar, Elizabeth A.

AU - Cranston, Ross D.

AU - Weber, Kathleen M.

AU - Burk, Robert D.

AU - Wiley, Dorothy J.

AU - Reddy, Susheel

AU - Margolick, Joseph B.

AU - Strickler, Howard

AU - Wentz, Alicia

AU - Jacobson, Lisa

AU - Coles, Christian L.

AU - Bream, Jay H.

AU - Rositch, Anne F.

AU - Guo, Yingshi

AU - Xiao, Weihong

AU - Gillison, Maura L.

AU - D’Souza, Gypsyamber

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: Persistent oral human papillomavirus (HPV) infection increases risk for oropharyngeal carcinoma, and people living with HIV have higher rates of oral HPV infection and related cancers. Some prescription medications have immunomodulatory effects, but the impact of medication use on oral HPV natural history is unknown. Methods: Scope® oral rinse-and-gargle samples were collected semi-annually from 1,666 participants and tested for 37 types of oral HPV DNA using PCR; 594 HPV-infected participants with 1,358 type-specific oral HPV infections were identified. Data were collected on recent (past 6 months) use of medications. The relationship between medication use and oral HPV clearance was evaluated using Wei–Lin–Weissfeld regression, adjusting for biologic sex, prevalent versus incident infection, age, HIV status and CD4+ T cell count. Results: Out of 11 medications examined, oral HPV clearance was significantly reduced in participants reporting recent use of antipsychotics (HR 0.75, 95% CI 0.57–0.99), anxiolytics/sedatives (HR 0.78, 95% CI 0.63–0.96) and antidepressants (HR 0.82, 95% CI 0.67–0.999). Among antipsychotics users, effect modification by HIV status was observed, with reduced clearance in HIV-infected (HR 0.67, 95% CI 0.49–0.91), but not HIV-uninfected participants (p-interaction = 0.009). After adjusted analysis, antipsychotic use remained significantly associated with reduced oral HPV clearance overall (aHR 0.75, 95% CI 0.57–0.99), and when restricted to only HIV-infected participants (aHR 0.66, 95% CI 0.48–0.90). After adjustment, anxiolytic/sedative use and antidepressant use were no longer significantly associated with reduced oral HPV clearance. Conclusions: Some medications were associated with decreased oral HPV clearance, most notably antipsychotic medications. These medications are prescribed for conditions that may have immunomodulating effects, so characteristics of underlying illness may have partially contributed to reduced oral HPV clearance.

AB - Purpose: Persistent oral human papillomavirus (HPV) infection increases risk for oropharyngeal carcinoma, and people living with HIV have higher rates of oral HPV infection and related cancers. Some prescription medications have immunomodulatory effects, but the impact of medication use on oral HPV natural history is unknown. Methods: Scope® oral rinse-and-gargle samples were collected semi-annually from 1,666 participants and tested for 37 types of oral HPV DNA using PCR; 594 HPV-infected participants with 1,358 type-specific oral HPV infections were identified. Data were collected on recent (past 6 months) use of medications. The relationship between medication use and oral HPV clearance was evaluated using Wei–Lin–Weissfeld regression, adjusting for biologic sex, prevalent versus incident infection, age, HIV status and CD4+ T cell count. Results: Out of 11 medications examined, oral HPV clearance was significantly reduced in participants reporting recent use of antipsychotics (HR 0.75, 95% CI 0.57–0.99), anxiolytics/sedatives (HR 0.78, 95% CI 0.63–0.96) and antidepressants (HR 0.82, 95% CI 0.67–0.999). Among antipsychotics users, effect modification by HIV status was observed, with reduced clearance in HIV-infected (HR 0.67, 95% CI 0.49–0.91), but not HIV-uninfected participants (p-interaction = 0.009). After adjusted analysis, antipsychotic use remained significantly associated with reduced oral HPV clearance overall (aHR 0.75, 95% CI 0.57–0.99), and when restricted to only HIV-infected participants (aHR 0.66, 95% CI 0.48–0.90). After adjustment, anxiolytic/sedative use and antidepressant use were no longer significantly associated with reduced oral HPV clearance. Conclusions: Some medications were associated with decreased oral HPV clearance, most notably antipsychotic medications. These medications are prescribed for conditions that may have immunomodulating effects, so characteristics of underlying illness may have partially contributed to reduced oral HPV clearance.

KW - Antipsychotic

KW - Clearance

KW - HIV

KW - Immunomodulatory

KW - Oral HPV

KW - Prescription medication

UR - http://www.scopus.com/inward/record.url?scp=84994174462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994174462&partnerID=8YFLogxK

U2 - 10.1007/s10552-016-0826-2

DO - 10.1007/s10552-016-0826-2

M3 - Article

C2 - 27804058

AN - SCOPUS:84994174462

VL - 27

SP - 1491

EP - 1498

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 12

ER -